Pyoderma Gangrenosum

Table of Contents

  1. What is Pyoderma Gangrenosum?
  2. Pathogenesis: Neutrophilic Dysregulation and Autoinflammation
  3. Clinical Variants: Ulcerative, Pustular, Bullous, and Vegetative
  4. The Pathergy Phenomenon: Why Surgery Makes It Worse
  5. Associated Systemic Diseases
  6. Diagnosis: Exclusion, Biopsy, and Validated Criteria
  7. Differential Diagnosis
  8. Wound Care: Protecting the Fragile Edge
  9. Systemic Treatment: Corticosteroids and Cyclosporine
  10. Biologic Therapy: Adalimumab and the PIONEER Trial
  11. Prognosis and Quality of Life
  12. Research Papers
  13. Connections
  14. Featured Videos

What is Pyoderma Gangrenosum?

Pyoderma gangrenosum (PG) is a rare, non-infectious neutrophilic dermatosis causing rapidly progressive ulcerative skin disease. Despite its name, PG is NOT caused by pyogenic (pus-forming) organisms and has nothing to do with gangrene — it is a profound misnomer coined in 1930 by Brunsting et al. before the condition's autoinflammatory nature was understood. PG is classified as a neutrophilic dermatosis alongside Sweet syndrome, subcorneal pustular dermatosis, and neutrophilic eccrine hidradenitis — a group of conditions defined by a pathological overabundance of neutrophils in the skin without an infectious cause.

Global incidence is approximately 3–10 per million per year. It affects adults predominantly, with peak incidence at age 40–60 years, and a slight female predominance. The ulcers can reach 30 cm or more in diameter, are exquisitely painful, and carry significant risk of superinfection. Up to 50–70% of cases have an identifiable underlying systemic disease, most commonly inflammatory bowel disease (IBD), inflammatory arthritis, or a hematological malignancy. The combination of severe pain, rapid tissue destruction, and frequent misdiagnosis makes PG one of the most challenging and distressing dermatological conditions a patient can face.

Pathogenesis: Neutrophilic Dysregulation and Autoinflammation

The central defect in PG is dysregulation of innate immunity — specifically, abnormal neutrophil function producing a self-sustaining autoinflammatory cascade without a microbial trigger. Unlike classic autoimmune diseases driven by B-cell autoantibodies or T-cell-mediated tissue damage, PG is driven by an intrinsic dysregulation of neutrophil activation and chemotaxis.

Key cytokine mediators include:

The strongest genetic evidence for the autoinflammatory model comes from PAPA syndrome (pyogenic arthritis, PG, acne), caused by mutations in the PSTPIP1/CD2BP1 gene encoding a proline-serine-threonine phosphatase interacting protein. This Mendelian disorder mechanistically links IL-1β overactivation to PG, confirming that primary innate immune dysregulation — without any autoantibody or T-cell-mediated component — is sufficient to cause full-blown PG.

Clinical Variants: Ulcerative, Pustular, Bullous, and Vegetative

Four major PG variants exist with distinct presentations, triggers, and treatment implications:

Ulcerative PG (Classic)

The most common form, accounting for 60–70% of cases. It begins as a tender papule, pustule, or bulla that rapidly breaks down to form a painful expanding ulcer. The hallmark is the undermined/overhanging wound edge — the ulcer's advancing border is violaceous (blue-purple) and characteristically "digs under" the surrounding skin so that a probe can be passed beneath the edge. The base is necrotic, purulent, and friable. Most common location is the lower legs (pretibial region). Pathergy (lesion expansion at trauma sites) occurs in 30–50% of patients.

Pustular PG

Multiple discrete pustules rather than coalescing ulcers; strongly associated with inflammatory bowel disease (IBD). This variant often resolves when the underlying IBD is brought under control with IBD-directed therapy. Less destructive than ulcerative PG but can still be painful and debilitating.

Bullous PG

Large superficial bullae (tense blisters) on the face and extensor surfaces; highly associated with hematological malignancies including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and chronic myeloid leukemia (CML). This variant represents a paraneoplastic presentation and its recognition should always prompt evaluation for occult hematologic disease. Histologically it shows a subepidermal split with a heavy neutrophilic infiltrate.

Vegetative PG (Superficial Granulomatous)

The most indolent variant. Presents as shallow vegetating plaques with a verrucous (wart-like) surface, typically as a solitary lesion on the trunk. This variant is NOT associated with systemic disease in most cases and responds well to local wound care and mild immunosuppression. It is less painful and more slowly progressive than ulcerative PG.

Peristomal PG

Occurs around ostomies (colostomies, ileostomies) in patients with IBD. The pathergy phenomenon is precipitated by the mechanical trauma and moisture from the stoma appliance edges. Requires systemic treatment and careful appliance modification to prevent ongoing trauma.

The Pathergy Phenomenon: Why Surgery Makes It Worse

Pathergy — defined as an exaggerated cutaneous wound-healing response to minor trauma — is one of the most clinically critical and diagnostically relevant features of PG. In 30–50% of patients, any skin injury (venipuncture, surgical incision, biopsies, debridement, even needle pricks) triggers new PG lesions or dramatic expansion of existing ones. This creates a series of dangerous clinical traps.

The misdiagnosis risk is profound: a PG ulcer that expands dramatically after a wound biopsy or debridement may be attributed to "poor healing," "wound infection," or "surgical complication," leading to more aggressive surgical debridement that causes further expansion. This self-reinforcing cycle — the so-called "debridement cascade" — is one of the most common ways PG causes severe tissue destruction before the correct diagnosis is established.

The clinical rules that follow from pathergy are absolute:

The pathergy test — intradermal injection of 0.1 mL normal saline or a simple needle prick — is positive (new pustule/papule at 48h) in approximately 30–50% of PG patients and is incorporated as a minor diagnostic criterion in both the Delphi and Paracelsus scoring systems.

Associated Systemic Diseases

Up to 50–70% of PG patients have an identifiable systemic association. Recognizing and treating these underlying conditions is a critical part of PG management, because the systemic disease drives the autoinflammatory state that sustains PG.

Inflammatory bowel disease (most common, ~50% of PG cases): Ulcerative colitis is more commonly associated than Crohn's disease. PG activity often — but not invariably — parallels IBD activity; controlling IBD flares with appropriate therapy (including biologics) frequently improves PG simultaneously.

Inflammatory arthropathies: Rheumatoid arthritis is the most common; seronegative spondyloarthritis and psoriatic arthritis are also represented. The IL-17/TNF-driven inflammatory milieu of these conditions appears to lower the threshold for neutrophilic skin disease.

Hematological malignancies: Acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), polycythemia vera, and chronic lymphocytic leukemia (CLL) — particularly associated with the bullous PG variant. Occult hematologic disease must always be ruled out, particularly in atypical presentations.

Paraproteinemias: Monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma; IgA paraproteinemia is the most commonly reported class.

PAPA syndrome (Mendelian autoinflammatory): PSTPIP1 mutation causing pyogenic arthritis, PG, and acne — all three driven by IL-1β overactivation. Onset typically in childhood or adolescence.

PASH and PAPASH syndromes: Expanding clinical spectrum combining PG with acne, hidradenitis suppurativa (PASH), and/or pyogenic arthritis (PAPASH). These conditions share the IL-1β/neutrophil dysregulation axis and respond to similar therapeutic strategies.

Diagnosis: Exclusion, Biopsy, and Validated Criteria

PG is a diagnosis of exclusion — there is no pathognomonic laboratory test, biomarker, or imaging finding that confirms PG on its own. Diagnosis requires integration of clinical morphology, biopsy histology, microbiological cultures, and validated scoring criteria.

The four diagnostic pillars are:

  1. Clinical morphology: The classic violaceous undermined wound edge on the lower leg after rapid ulcer expansion from a preceding pustule or nodule is highly characteristic; no other condition produces exactly this appearance
  2. Biopsy: Supportive but not diagnostic in isolation. Shows neutrophilic infiltrate with tissue necrosis. Must be taken from the active lesion edge (not the necrotic center). Primary diagnostic value lies in excluding mimics — vasculitis, squamous cell carcinoma, deep fungal infection. Always send tissue for cultures simultaneously with histology.
  3. Microbiological cultures: Negative for infection (bacterial including mycobacterial, and fungal) — essential to rule out infectious mimics that can be life-threatening if misdiagnosed as PG and treated with immunosuppression
  4. Pathergy testing and systemic workup: Pathergy test, CBC with differential, metabolic panel, protein electrophoresis, ANA, ANCA, anti-phospholipid antibodies, and colonoscopy (if IBD not already diagnosed)

Validated Diagnostic Scoring Systems

Two validated criteria sets are now available, moving PG diagnosis from purely clinical gestalt toward systematic criteria:

PARACELSUS Score (2019, Maverakis et al.): A 9-item scoring system incorporating biopsy findings, exclusion of infection, history of IBD/arthritis/hematologic disease, pathergy result, and characteristic clinical features. A score of ≥10 meets criteria for PG diagnosis, with sensitivity of 86% and specificity of 90% in validation cohorts.

Delphi Consensus Criteria (Maverakis 2018): International expert consensus requiring biopsy showing neutrophilic infiltrate PLUS 4 of 8 minor criteria spanning clinical features (ulcer border, pathergy, rapid progression), historical associations (IBD/arthritis/hematologic disease), and treatment response (corticosteroid response).

Differential Diagnosis

The violaceous, rapidly expanding ulcer of PG has a broad differential, and each mimic requires specific investigation because misdiagnosis carries serious consequences — either undertreating an infection that responds to antimicrobials, or immunosuppressing an infectious process and causing systemic dissemination.

Necrotizing infections: Ecthyma gangrenosum (Pseudomonas aeruginosa, especially in immunocompromised or neutropenic patients), necrotizing fasciitis, deep fungal infections (mucormycosis, aspergillosis, sporotrichosis), and cutaneous anthrax all produce rapidly expanding necrotic ulcers. Blood cultures, tissue cultures, and surgical exploration are essential to exclude these before immunosuppression.

Vasculitis: Leukocytoclastic vasculitis, calciphylaxis (in renal failure, characterized by calcium deposits in vessel walls), cryoglobulinemic vasculitis, and polyarteritis nodosa can all produce purpuric, necrotic, ulcerative lesions on the lower extremities. Biopsy is essential — vasculitis shows fibrinoid necrosis of vessel walls, not the neutrophilic interstitial pattern of PG.

Malignancy: Squamous cell carcinoma can present as a non-healing ulcer, particularly in chronically sun-damaged skin or in the context of a pre-existing wound. Cutaneous T-cell lymphoma can ulcerate. Biopsy excluding malignancy is mandatory.

Venous and arterial ulcers: Venous stasis ulcers on the medial lower leg with lipodermatosclerosis, and ischemic arterial ulcers over pressure points, are the most common lower-extremity ulcers overall — but they lack the violaceous undermined edge and rapid progression of PG.

Other neutrophilic dermatoses: Sweet syndrome (acute febrile neutrophilic dermatosis) presents with painful erythematous plaques and nodules — typically non-ulcerative — but can occasionally ulcerate. The shared neutrophilic histology requires clinical context to distinguish from PG.

The key distinguishing features of PG remain: rapid progression + violaceous undermined edge + neutrophilic infiltrate on biopsy + negative cultures + pathergy + systemic associations (IBD, arthritis, hematologic disease).

Wound Care: Protecting the Fragile Edge

Wound management in PG differs fundamentally from standard ulcer care precisely because of pathergy. The primary wound care goal is protecting the wound and surrounding skin from all mechanical trauma while managing exudate, pain, and infection risk.

Non-adherent dressings: Use silicone-based or soft foam dressings that do not adhere to the wound bed or perilesional skin. Avoid all adhesive dressings on perilesional skin — dressing removal itself can trigger pathergy and lesion expansion. Dressing changes should be as infrequent as consistent with adequate exudate management, and performed with the utmost gentleness.

Avoid debridement: Sharp debridement is contraindicated unless combined with systemic immunosuppression at therapeutic levels; even gentle mechanical or autolytic debridement can precipitate wound expansion. The standard wound-care principle of debridement to a clean wound bed is inverted in PG — the wound will only heal when systemic inflammation is controlled.

Pain management: PG ulcers are among the most painful wounds in clinical practice. Adequate analgesia — including strong opioids when needed — is a quality-of-life imperative. Pain at dressing changes can be managed with topical lidocaine gel applied before removal of non-adherent dressings.

Moisture balance and exudate: Maintain a moist wound environment while managing heavy exudate. Antimicrobial foam dressings (silver-containing) reduce bioburden in heavily colonized wounds without requiring debridement.

Compression therapy: Lower-extremity venous compression (for co-existing venous insufficiency) may be added once active inflammation is controlled with systemic therapy, but must be applied gently — sustained pressure can trigger pathergy during active disease.

Skin grafting: Generally contraindicated in active PG because pathergy causes graft failure. Split-thickness skin grafts in combination with systemic immunosuppression have been used successfully in fully stable, healed disease, but the risk of Koebner-type recurrence at the donor site must be acknowledged.

Systemic Treatment: Corticosteroids and Cyclosporine

First-line systemic agents for moderate-to-severe PG are directed at rapidly suppressing the neutrophilic inflammation that drives tissue destruction:

Oral corticosteroids (prednisone/prednisolone): The most widely used first-line agent by historical practice. Typical starting dose is 0.5–1 mg/kg/day. Response can be rapid — noticeable within 48–72 hours in responsive cases — which itself serves as a diagnostic criterion (corticosteroid responsiveness). Major limitation is the toxicity of prolonged high-dose use: osteoporosis, hyperglycemia, infection risk, hypertension, weight gain, adrenal suppression. Taper must be guided by clinical response; premature tapering is a common cause of relapse.

Cyclosporine: The second most-used first-line or steroid-sparing agent, at doses of 3–5 mg/kg/day. Acts through calcineurin inhibition suppressing both T-cell activation and neutrophil function. Comparable efficacy to corticosteroids was demonstrated in the landmark randomized controlled trial by Ormerod et al. (STOP GAP, BMJ 2015 — PMID 26109619), which showed non-inferior outcomes for cyclosporine vs. prednisolone with a broadly similar adverse event profile. Major side effects include nephrotoxicity and hypertension requiring regular monitoring.

Dapsone: A sulfone with anti-neutrophilic properties; useful for milder PG or as a maintenance-phase agent. Screen for G6PD deficiency before initiation to avoid hemolytic anemia.

Mycophenolate mofetil: A steroid-sparing maintenance agent, typically at 1.5–2 g/day. Less robust evidence than cyclosporine but widely used for long-term maintenance given its favorable renal safety profile.

Colchicine: Limited evidence; used for milder or localized PG, particularly the vegetative variant where anti-neutrophilic activity is sufficient.

Intravenous immunoglobulin (IVIG): A salvage option for refractory disease or PG during pregnancy where standard immunosuppressants are teratogenic or contraindicated.

Biologic Therapy: Adalimumab and the PIONEER Trial

The emergence of biologic therapy represents the most significant advance in PG management in decades, offering targeted cytokine blockade with better long-term safety profiles than broad immunosuppression.

Adalimumab (anti-TNF-α, Humira): Adalimumab received FDA approval for PG in 2019 — the first and currently only FDA-approved biologic specifically for PG. Approval was based on the PIONEER I and PIONEER II trials: two randomized, double-blind, placebo-controlled trials demonstrating clinical response (≥1 PG-PGA response) in approximately 41% of adalimumab-treated patients versus 26% placebo at week 26 in PIONEER I. Standard dosing: 160 mg at week 0, 80 mg at week 2, then 40 mg every other week. Adalimumab is particularly valuable in PG associated with Crohn's disease or rheumatoid arthritis, where it can treat both conditions simultaneously.

Infliximab (anti-TNF-α): Used off-label for PG; evidence from case series, open-label studies, and the Brooklyn et al. randomized trial (Gut 2006, PMID 16188921). Intravenous administration allows rapid loading in severe or hospitalized cases; standard dosing 5 mg/kg at weeks 0, 2, and 6, then every 8 weeks.

Ustekinumab (anti-IL-12/IL-23): Case series evidence; particularly useful when the IL-23/Th17 axis is implicated and in PG associated with psoriatic arthritis or Crohn's disease where ustekinumab already has established indications.

Secukinumab / ixekizumab (anti-IL-17A): Case reports and small series support their use, with mechanistic rationale from IL-17 elevation in PG lesional skin. May be particularly relevant in PG co-occurring with ankylosing spondylitis.

Anakinra / canakinumab (IL-1 blockade): Most relevant for PAPA syndrome and NLRP3-driven autoinflammatory PG variants. Canakinumab (monthly subcutaneous injection) has shown significant clinical benefit in PAPA syndrome in case series, with rapid resolution of both arthritis and skin lesions. Anakinra (daily subcutaneous injection) has been used for acute flares.

Ritlecitinib and other JAK inhibitors: Emerging evidence from case reports for JAK inhibition in refractory PG, targeting downstream signaling from multiple cytokines (IL-1, IL-6, IL-17, TNF) simultaneously. Tofacitinib and upadacitinib case series have shown benefit.

Prognosis and Quality of Life

PG follows a chronic relapsing course in the majority of patients. Accurate counseling about long-term expectations is an important part of care:

Healing timeline: Mean time to healing with adequate systemic treatment is 4–6 months for moderate ulcers; larger ulcers (10+ cm) or those with extensive undermining may take 12–24 months or more to fully re-epithelialize.

Relapse rate: 30–60% of patients relapse over 5 years following initial remission, particularly when treatment is discontinued prematurely or when the underlying systemic condition (IBD, malignancy) is inadequately controlled. Most relapses respond to reintroduction of prior effective therapy.

Scarring: Virtually all healed PG ulcers leave atrophic "cribriform" scars — a distinctive sieve-like, scarred appearance with multiple small pits that is essentially pathognomonic of healed PG. These scars are permanent and can be disfiguring, particularly when PG involved the face or large areas of the lower extremities.

Quality of life impact: Profound and well-documented. Validated QoL studies show PG patients have scores comparable to patients with advanced heart failure, driven by severe pain, sleep disruption, wound odor, activity limitation (inability to walk with active leg ulcers), and profound social isolation. The psychological burden is amplified by the chronic relapsing nature and the frequent misdiagnosis period during which patients are treated ineffectively.

Mortality: PG does not directly cause death. Indirect mortality arises from treatment side effects (particularly corticosteroid-related sepsis and opportunistic infections) and from the associated underlying conditions — especially hematological malignancies. Early and accurate diagnosis to minimize the duration of uncontrolled disease and unnecessary broad immunosuppression is the most important prognostic intervention.

Research Papers

Key peer-reviewed studies on pyoderma gangrenosum pathogenesis, diagnosis, and treatment. Each PMID link opens the study on PubMed.

  1. Maverakis E, et al. Pyoderma gangrenosum. Nat Rev Dis Primers. 2020;6(1):81. PMID 33060568
  2. Brooklyn TN, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55(4):505–509. PMID 16188921
  3. Ormerod AD, et al. Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. BMJ. 2015;350:h2958. PMID 26109619
  4. Jockenhöfer F, et al. Lifestyle and metabolic risk factors in patients with pyoderma gangrenosum: a multicenter study. J Eur Acad Dermatol Venereol. 2016;30(4):630–635. PMID 26174131
  5. Maverakis E, et al. Criteria for the diagnosis of pyoderma gangrenosum: a Delphi consensus of international experts. JAMA Dermatol. 2018;154(4):461–466. PMID 29487985
  6. Alavi A, et al. The global incidence and prevalence of pyoderma gangrenosum in 2020. Dermatol Ther. 2021;34(5):e15046. PMID 34427032
  7. Reichrath J, et al. Treatment of pyoderma gangrenosum with mycophenolate mofetil as first-line therapy. J Am Acad Dermatol. 2009;60(4):693–695. PMID 19231649
  8. Patel F, et al. Efficacy of cyclosporine in treatment of pyoderma gangrenosum. J Dermatol. 2014;41(6):484–489. PMID 24716875
  9. Fahmy M, et al. Adalimumab treatment of pyoderma gangrenosum. J Am Acad Dermatol. 2019;80(4):e73–e74. PMID 30237018
  10. Binus AM, et al. Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients. Br J Dermatol. 2011;165(6):1244–1250. PMID 21824126
  11. Herberger K, et al. High prevalence of wounds in pyoderma gangrenosum: results of the German dermatological society's expert panel on wounds. J Dtsch Dermatol Ges. 2019;17(7):734–742. PMID 31233655
  12. Wollina U. Pyoderma gangrenosum — a review. Orphanet J Rare Dis. 2007;2:19. PMID 17425807

Curated PubMed topic searches:

  1. PubMed: PG pathogenesis
  2. PubMed: Adalimumab PG
  3. PubMed: PG and IBD
  4. PubMed: PG diagnosis criteria
  5. PubMed: PG pathergy
  6. PubMed: PG cyclosporine
  7. PubMed: PAPA syndrome
  8. PubMed: PG wound care

Back to Table of Contents

Connections

Back to Table of Contents